胸腺法新治疗普通型新型冠状病毒肺炎临床分析

Clinical analysis of the effect of thymalfasin on common type patients with COVID-19

目的观察胸腺法新治疗普通型新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)的疗效。方法选取2020年1月29日—2020年3月20日在成都市公共卫生临床医疗中心治疗出院的26例细胞免疫功能降低(CD4^(+)T计数<410个/μL)的普通型COVID-19病例,依据是否使用了胸腺法新治疗分为对照组及观察组。对照组使用重组人干扰素α-2β、阿比多尔或洛匹那韦/利托那韦,同时联合中药治疗。观察组在对照组基础上加用胸腺法新皮下注射,比较两组的治疗效果。结果两组患者的年龄、性别、病情、CD4^(+)T及CD8^(+)T计数基线均无明显差异,具有可比性,均在出院后按时完成随访复诊。两组新型冠状病毒(SARS-CoV-2)核酸转阴时间、住院时间、核酸复阳率、出院时的C反应蛋白(CRP)及血清淀粉样蛋白(SAA)均无明显差异(P>0.05)。两组出院时的CD4^(+)T计数及CD8^(+)T计数均较入院时升高(P<0.05),升高程度的差异无统计学意义(P>0.05)。结论本研究未显示对细胞免疫功能降低的普通型COVID-19患者按说明书用量使用胸腺法新治疗能得到确切的临床获益。

Objective We observed the effect of thymalfasin on common type patients with COVID-19.Methods A total of 26 cases of common type COVID-19 patients with had reduced cellular immune function(CD4+T counts<410 cells/μL)in the Public and Health Clinical Center of Chengdu and discharged from January 29,2020 to March 20,2020 were included as research objects,and they were divided into control group and observation group,depending on whether or not the thymalfasin method is used.The patients in control group used recombinant human interferonα-2β,abidor or lopinavir/ritonavir,and traditional Chinese medicine,the observation group extra added thymalfasin.Then the treatment effect were compared between the two groups.Results There were no significant difference in age,gender,condition and the baseline CD4^(+)T and CD8^(+)T counts between the two groups,the cases were all followed up at our hospital after discharge.There was no significant difference in time of SARS-CoV-2 nucleic acid turning negative,hospital stay,nucleic acid re-positive rate,C-reactive protein and serum amyloid protein(SAA)at discharge between the two groups(P>0.05).The CD4^(+)T count and CD8^(+)T count at discharge in two groups were both higher than those on admission(P<0.05),there were no statistical significances in the degree of elevation between the two groups(P>0.05).Conclusion The study does not show that common type COVID-19 patients who had reduced cellular immune function can obtain definite clinical benefits by using the thymalfasin according to the instructions.